Hence, it is logical to speculate that the relative ratio of EGFR/MET may serve as a predictive biomarker for EGFR inhibitor treatment in NSCLC patients and warrants further investigation in an expanded prospective clinical trial. Here, EGFR is linked to non-small cell lung carcinoma.